-
2022-502185-24-00
5
Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
-
2022-502365-26-00
5
Asthma
-
2024-513724-42-00
10
Medulloblastoma
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517295-37-00
5
low and intermediate risk neuroblastoma
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-524038-24-00
5
2026-05-22
Focal Epilepsy
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2024-514974-39-00
5
2025-10-10
Developmental and Epileptic Encephalopathies (DEEs)
-
2024-516792-32-01
4
2025-07-18
Metastatic non-squamous non-small cell lung cancer
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2023-506605-19-00
5
2025-02-11
Bipolar depression
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2022-502359-75-00
5
2024-07-03
Dravet syndrome
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2024-518520-77-00
4
2021-11-24
Myclonic-astatic epilepsy